<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03776760</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1802</org_study_id>
    <nct_id>NCT03776760</nct_id>
  </id_info>
  <brief_title>Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination</brief_title>
  <acronym>SCALE-C</acronym>
  <official_title>Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Australian Health and Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flinders University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A community-based &quot;test and treat&quot; intervention integrating point-of-care HCV RNA testing,
      non-invasive liver disease assessment and linkage to care will lead to a reduction in HCV
      prevalence among people attending Aboriginal health services.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCALE-C is an interventional cohort study recruiting people with or at risk of HCV infection
      from Aboriginal health services in Australia. Participants will be screened for HCV infection
      using point-of-care testing (anti-HCV antibody and/or HCV RNA). People with current HCV
      infection (HCV RNA positive) will be offered treatment with eight or 12 weeks of
      pan-genotypic DAA therapy, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir, as available
      on the PBS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hepatitis C prevalence</measure>
    <time_frame>Week 0 to week 144</time_frame>
    <description>Change in the proportion of people with current HCV infection (HCV RNA positive)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hepatitis C incidence</measure>
    <time_frame>Week 0 to week 144</time_frame>
    <description>Change in HCV incidence will be calculated using person-time of observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAA uptake</measure>
    <time_frame>To week 144</time_frame>
    <description>Proportion with HCV infection initiating DAA therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response rate (SVR12 rate)</measure>
    <time_frame>From week 0 to Week 144</time_frame>
    <description>Overall SVR12 rate in those who commence treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV reinfection incidence post treatment</measure>
    <time_frame>6 monthly from end of treatment until week 144</time_frame>
    <description>Participants will be assessed six monthly post end of treatment for HCV recurrence.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HCV Transmission networks within the Aboriginal community</measure>
    <time_frame>At screening for all participants</time_frame>
    <description>HCV viral genome for will be sequenced for all participants from their screening sample. The sequences ill be used for develop a phylogenetic tree which can be used to determine transmission networks within the study population.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis</condition>
  <condition>Liver Diseases</condition>
  <condition>Hepatitis, Viral, Human</condition>
  <condition>RNA Virus Infections</condition>
  <condition>Digestive System Diseases</condition>
  <arm_group>
    <arm_group_label>Fingerstick Point of Care GeneXpert HCV Test</arm_group_label>
    <description>Participants will have HCV testing using the finger-stick point of care GeneXpert quantitative HCV RNA assay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat - SOF/VEL</arm_group_label>
    <description>Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - sofosbuvir/velpatesvir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat - G/P</arm_group_label>
    <description>Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - glecaprevir/pibrentasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fingerstick GeneXpert HCV RNA quantitative assay</intervention_name>
    <description>All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly</description>
    <arm_group_label>Fingerstick Point of Care GeneXpert HCV Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir/velpatesvir</intervention_name>
    <description>Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia</description>
    <arm_group_label>Fingerstick Point of Care GeneXpert HCV Test</arm_group_label>
    <arm_group_label>Treat - SOF/VEL</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glecaprevir/pibrentasvir</intervention_name>
    <description>Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia</description>
    <arm_group_label>Fingerstick Point of Care GeneXpert HCV Test</arm_group_label>
    <arm_group_label>Treat - G/P</arm_group_label>
    <other_name>Maviret</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried Blood Spot samples for HCV RNA viral load testing and viral genome sequencing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People attending Aboriginal health services will be invited to receive HCV RNA testing
        using the GeneXpert fingerstick HCV RNA assay. Those found to have active HCV infection
        will be offered treatment with one of two pan-genotypic direct acting antiviral therapies
        available in Australia (SOF/VEL or G/P)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older;

          -  voluntarily signed the informed consent form.

        Exclusion Criteria:

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerard Estivill</last_name>
    <phone>+612 9385 0900</phone>
    <email>gestivill@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jullums Lismore Aboriginal Medical Service</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Silberberg</last_name>
      <phone>+612 6621 4366</phone>
      <email>peter@jullums.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walhallow Aboriginal Corporation</name>
      <address>
        <city>Quirindi</city>
        <state>New South Wales</state>
        <zip>2343</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suruchi Amarasena, MBBS</last_name>
      <phone>+612 6746 2001</phone>
      <email>suruchiaaa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Lincoln Aboriginal Health Service</name>
      <address>
        <city>Port Lincoln</city>
        <state>South Australia</state>
        <zip>5606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Bilney</last_name>
      <phone>+618 8683 0162</phone>
      <email>Sharon.Bilney@plahs.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

